HIV-infected patients have metabolic abnormalities that put them at increased risk of
cardiovascular disease (CVD), including abnormalities associated with HIV infection itself …

For the past several decades, humanity has been dealing with HIV. This disease is one of
the biggest global health problems. Fortunately, modern antiretroviral therapy allows …

Highly active antiretroviral therapy (HAART) has significantly improved the prognosis for
many individuals with HIV infection. Consequently, HIV infection has become a chronic and …

Background: Antiretroviral agents, particularly protease inhibitors (PIs), may adversely affect
lipid levels in patients with HIV infection. However, it is not known whether HIV-associated …

Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …

Introduction Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

Human immunodeficiency virus (HIV) is a chronic disease associated with dyslipidemia and
insulin resistance. In addition, the administration of combination antiretroviral therapy is …

Background Dyslipidaemia is a common metabolic condition occurring in people with HIV
(PWH), whether treated or untreated with antiretroviral therapy (ART). As people live longer …

Since the discovery and development of antiretroviral therapy (ART), HIV has become a
chronic disease with patients living longer lives and to ages where co‐morbidities, such as …

In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with
human immunodeficiency virus infection, the mean changes in low-density lipoprotein …